Description: <p><b>Turmerones</b> — Turmerones are lipophilic volatile sesquiterpenes from turmeric rhizome oil, mainly ar-turmerone, α-turmerone, and β-turmerone. They are distinct from curcuminoids and should not be treated as curcumin synonyms. Formal classification: plant-derived volatile oil constituents / sesquiterpene ketones. Standard abbreviations include ATM or ar-T for aromatic turmerone, and α-TUR / β-TUR for α- and β-turmerone.
Separate database product from whole turmeric or curcumin, because turmerones have different PK, BBB penetration, P-gp modulation, and apoptosis mechanisms from curcumin.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>ROS-linked mitochondrial and death-receptor apoptosis, especially reported for ar-turmerone in hepatocellular carcinoma and leukemia models.</li>
<li>Growth suppression and programmed cell death in selected cancer cell lines, with strongest support in preclinical leukemia and hepatocellular carcinoma studies.</li>
<li>Migration and invasion suppression in glioma models through cathepsin B and P27-related signaling.</li>
<li>Inflammation and stress-pathway modulation, including NF-κB, JNK, p38 MAPK, COX-2, iNOS, cytokines, and MMP-related axes, mostly context-dependent.</li>
<li>Curcumin bioavailability and transporter modulation, including altered Caco-2 transport and mixed P-gp effects depending on the turmerone isomer.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Turmerones are more lipophilic than curcumin and are relevant as turmeric-oil constituents and as curcumin bioavailability modifiers. Reported animal PK suggests measurable systemic exposure, moderate oral bioavailability for major turmeric-oil constituents, and meaningful brain distribution. Human therapeutic PK for isolated turmerones remains insufficient.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer experiments use tens of μg/mL concentrations, which may exceed typical achievable free systemic exposure after ordinary turmeric intake. Turmeric oil or enriched turmerone formulations may increase exposure, but cancer-cell IC50 values should be treated as preclinical screening concentrations rather than clinically validated dosing targets.</p>
<p><b>Clinical evidence status:</b> Preclinical. There is no strong cancer clinical-trial evidence for isolated turmerones. Human turmeric oil safety data and curcumin/turmeric-formulation trials do not establish turmerone-specific oncology efficacy. Recommended database status: add as a separate mechanistic/preclinical product, linked to turmeric oil and curcumin as related entries.</p>
<h3>Turmerones Cancer Mechanism Table</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mitochondrial ROS apoptosis</td>
<td>↑ ROS, ↓ mitochondrial membrane potential, ↑ Bax, ↑ PUMA, ↑ cytochrome c release, ↑ caspase-9, ↑ caspase-3</td>
<td>Likely lower selectivity margin not fully established</td>
<td>R/G</td>
<td>Apoptosis induction</td>
<td>Core ar-turmerone mechanism in hepatocellular carcinoma models; high concentration only; model-dependent</td>
</tr>
<tr>
<td>2</td>
<td>Death receptor apoptosis</td>
<td>↑ Fas, ↑ DR4, ↑ caspase-8, ↑ caspase-3</td>
<td>Insufficient direct comparison</td>
<td>R/G</td>
<td>Extrinsic apoptosis support</td>
<td>Appears coupled to ROS and MAPK stress signaling rather than a fully independent primary trigger</td>
</tr>
<tr>
<td>3</td>
<td>JNK and ERK stress signaling</td>
<td>↑ JNK, ↑ ERK, ↑ pro-apoptotic signaling</td>
<td>Context-dependent</td>
<td>R/G</td>
<td>Amplifies apoptosis</td>
<td>Stress-kinase activation appears downstream of ROS in hepatocellular carcinoma models</td>
</tr>
<tr>
<td>4</td>
<td>Programmed cell death in leukemia</td>
<td>↑ DNA fragmentation, ↑ apoptotic morphology, ↓ viability</td>
<td>Some selectivity reported versus selected non-target cells, but evidence remains limited</td>
<td>G</td>
<td>Cytotoxic apoptosis</td>
<td>Older but relevant evidence supports ar-turmerone and related turmeric-oil constituents as apoptosis inducers in leukemia models</td>
</tr>
<tr>
<td>5</td>
<td>Glioma cathepsin B and P27 axis</td>
<td>↓ cathepsin B, ↓ P27 cleavage, ↓ proliferation, ↓ mobility</td>
<td>Not well defined</td>
<td>G</td>
<td>Reduced proliferation and migration</td>
<td>Potential CNS-oncology relevance because ar-turmerone is brain-penetrant; still preclinical</td>
</tr>
<tr>
<td>6</td>
<td>NF-κB inflammatory axis</td>
<td>↔/↓ NF-κB depending on model and stimulus</td>
<td>↓ NF-κB activation in inflammatory microglial models</td>
<td>R/G</td>
<td>Anti-inflammatory and context-dependent anticancer support</td>
<td>curcuminoids suppress NF-κB more consistently than turmerones in some comparative studies</td>
</tr>
<tr>
<td>7</td>
<td>COX-2 iNOS MMP inflammatory mediators</td>
<td>↓ COX-2, ↓ MMP-related signaling (context-dependent)</td>
<td>↓ iNOS, ↓ COX-2, ↓ MMP-9 in activated microglia</td>
<td>G</td>
<td>Reduced inflammatory mediator output</td>
<td>More relevant to inflammation, tumor microenvironment, and AD than direct tumor killing</td>
</tr>
<tr>
<td>8</td>
<td>P-gp and curcumin transport</td>
<td>↔ P-gp activity depending on isomer; ↑ curcumin cellular transport in Caco-2 model</td>
<td>↔ drug-transporter interaction risk</td>
<td>R</td>
<td>Bioavailability and drug-interaction modulation</td>
<td>α-turmerone and ar-turmerone have different transporter effects; this is a key reason to keep turmerones separate from curcumin</td>
</tr>
<tr>
<td>9</td>
<td>Chemosensitization</td>
<td>Possible ↑ intracellular exposure of co-administered compounds through transporter effects</td>
<td>Possible altered exposure to normal tissues</td>
<td>R/G</td>
<td>Unproven adjunct potential</td>
<td>Mechanistically plausible but not clinically established for oncology; not a strong chemosensitizer </td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Preclinical activity often requires high μg/mL concentrations</td>
<td>Oral oil safety appears better supported than isolated high-dose oncology use</td>
<td>G</td>
<td>Limits clinical confidence</td>
<td>Major constraints are exposure, formulation, isomer composition, lack of isolated-turmerone cancer trials, and potential transporter-mediated interactions</td>
</tr>
</tbody>
</table>
<p>P:0–30 min R:30 min–3 hr G:>3 hr</p>